Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut; VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, Connecticut; Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington, Connecticut.
Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut; VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, Connecticut.
Am J Prev Med. 2023 Sep;65(3):528-533. doi: 10.1016/j.amepre.2023.03.005. Epub 2023 Mar 12.
Cannabis use for medical purposes is legalized across 39 states and the District of Columbia in the U.S. The objective of this study was to evaluate temporal trends and correlates of cannabis use for medical purposes in the U.S.
Data from the 2013-2020 National Survey on Drug Use and Health were used. Since 2013, medical cannabis use has been assessed using a dichotomous question asking whether any medical cannabis use was recommended by a doctor among those who used cannabis in the past 12 months. A modified Poisson model was used to estimate the average annual percentage change in medical cannabis use from 2013 to 2020. The analyses were repeated for key sociodemographic and clinical subgroups. Data were analyzed from September to November 2022.
The prevalence of U.S. residents using cannabis for medical purposes increased significantly from 1.2% in 2013-2014 to 2.5% in 2019-2020, with an average annual percentage change of 12.9% (95% CI=10.4, 15.5), and many of sociodemographic and clinical subgroups showed similar significant increases in cannabis use for medical purposes. In the multivariable-adjusted model, living in a state that legalized medical cannabis remained significantly associated with medical cannabis use (AOR=4.10; 95% CI=3.68, 4.56).
The study documents a continued nationwide increase in the use of cannabis for diverse medical purposes between 2013 and 2020, two decades after the first state passed legalizing legislation.
在美国,39 个州和哥伦比亚特区已将医用大麻合法化。本研究旨在评估美国医用大麻使用的时间趋势和相关因素。
本研究使用了 2013-2020 年全国毒品使用与健康调查的数据。自 2013 年以来,医用大麻的使用情况通过一个二分问题进行评估,即在过去 12 个月中使用大麻的人群中,有多少人曾被医生建议使用医用大麻。采用修正泊松模型估计 2013 年至 2020 年医用大麻使用的平均年百分比变化。对关键的社会人口学和临床亚组进行了重复分析。数据于 2022 年 9 月至 11 月进行分析。
美国居民医用大麻的使用率从 2013-2014 年的 1.2%显著增加到 2019-2020 年的 2.5%,平均年百分比变化为 12.9%(95%CI=10.4, 15.5),许多社会人口学和临床亚组的医用大麻使用率也显示出类似的显著增加。在多变量调整模型中,生活在医用大麻合法化的州与医用大麻的使用显著相关(AOR=4.10;95%CI=3.68, 4.56)。
本研究记录了 2013 年至 2020 年间,全美医用大麻的使用呈持续增长趋势,这是首个州通过医用大麻合法化立法的 20 年后。